Akebia Therapeutics, Inc. - Common Stock (AKBA)

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Equity / Common Stock
Shares outstanding
266,941,931
Total 13F shares
81,183,875
Share change
-15,624,829
Total reported value
$58,271,372
Put/Call ratio
61%
Price per share
$0.72
Number of holders
115
Value change
-$32,826,439
Number of buys
52
Number of sells
69

Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2022

As of 31 Mar 2022, Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by 115 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 81,183,875 shares. The largest 10 holders included VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, SATTER MANAGEMENT CO., L.P., JPMORGAN CHASE & CO, GEODE CAPITAL MANAGEMENT, LLC, DIMENSIONAL FUND ADVISORS LP, MILLENNIUM MANAGEMENT LLC, FEDERATED HERMES, INC., and Orchard Capital Managment, LLC. This page lists 115 institutional shareholders reporting positions in this security for the Q1 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.